Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 4Terminated 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1Lymphoid 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × IL32 protein, human × Clear all
NCT02100891 2025-03-19

STIR

Medical College of Wisconsin

Phase 2 Terminated
15 enrolled 11 charts
CNSSarcoma

Brain Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms

NCT01106950 2017-12-28

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
15 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00941928 2014-05-22

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 3 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡